Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Neonatal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 1 · 14.3%Moderate 2 · 28.6%High 0 · 0%

Intravenous immunoglobulin plus phototherapy vs phototherapy alone

Use of ET (≥ 1); all studies · neonates with alloimmune hemolytic disease

It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of ET (≥ 1); all studies compared with phototherapy alone (very low certainty).

1 finding from 1 review

Immunoglobulin for alloimmune hemolytic disease in neonates 2018 · Cochrane Headline outcomes only
RR 0.35 [0.25, 0.49]
9 studies · 658 participants
Very low

Intravenous immunoglobulin plus phototherapy vs phototherapy alone

Use of ET (≥ 1); placebo‐controlled studies · neonates with alloimmune hemolytic disease

Intravenous immunoglobulin plus phototherapy showed no clear difference in use of ET (≥ 1); placebo‐controlled studies compared with phototherapy alone (moderate certainty).

1 finding from 1 review

Immunoglobulin for alloimmune hemolytic disease in neonates 2018 · Cochrane Headline outcomes only
RR 0.98 [0.48, 1.98]
2 studies · 172 participants
Moderate

Intravenous immunoglobulin plus phototherapy vs phototherapy alone

ETs performed per infant; all studies · neonates with alloimmune hemolytic disease

1 finding from 1 review

Immunoglobulin for alloimmune hemolytic disease in neonates 2018 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 658 participants
Very low

Intravenous immunoglobulin plus phototherapy vs phototherapy alone

ETs performed per infant; placebo‐controlled studies · neonates with alloimmune hemolytic disease

1 finding from 1 review

Immunoglobulin for alloimmune hemolytic disease in neonates 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 172 participants
Moderate

Intravenous immunoglobulin plus phototherapy vs phototherapy alone

Use of top‐up transfusion in 1st week of life; all studies · neonates with alloimmune hemolytic disease

Intravenous immunoglobulin plus phototherapy showed no clear difference in use of top‐up transfusion in 1st week of life; all studies compared with phototherapy alone (low certainty).

1 finding from 1 review

Immunoglobulin for alloimmune hemolytic disease in neonates 2018 · Cochrane Headline outcomes only
RR 1.05 [0.65, 1.69]
4 studies · 378 participants
Low

Intravenous immunoglobulin plus phototherapy vs phototherapy alone

Use of top‐up transfusion after 1st week of life; all studies · neonates with alloimmune hemolytic disease

It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of top‐up transfusion after 1st week of life; all studies compared with phototherapy alone (very low certainty).

1 finding from 1 review

Immunoglobulin for alloimmune hemolytic disease in neonates 2018 · Cochrane Headline outcomes only
RR 1.16 [0.97, 1.38]
7 studies · 507 participants
Very low

Intravenous immunoglobulin plus phototherapy vs phototherapy alone

Maximum total serum bilirubin (µmol/L); all studies · neonates with alloimmune hemolytic disease

1 finding from 1 review

Immunoglobulin for alloimmune hemolytic disease in neonates 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 451 participants
Very low